BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28

• 

  Job Trends

  Lilly Pumps $700M into Boston-Based RNA Therapeutics Facility

  Eli Lilly is investing $700 million to build a state-of-the-art facility in Boston, as part of plans to advance its RNA-based therapeutics research and development activities.

  February 22, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Policy

  Malawi Declares Polio Outbreak Following New Case in Lilongwe

  Health authorities in Malawi discovered an outbreak of wild poliovirus type 1 on Thursday. The announcement comes after a case was detected in a young child in Lilongwe.

  February 22, 2022

   · 

  2 min read

   · 

  Rosemary Scott
• 

  Policy

  CDC Under Fire for Allegedly Hoarding COVID-19 Data

  The U.S. Centers for Disease Control and Prevention is under fire for failing to publish large swaths of hospitalization data related to the COVID-19 pandemic.

  February 22, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Policy

  Five Confounding COVID Questions

  The COVID-19 pandemic and the virus that causes it, SARS-CoV-2, has been resilient, unpredictable and confounding from the very beginning.

  February 22, 2022

   · 

  6 min read

   · 

  Mark Terry
• 

  Drug Development

  Synairgen Crashes as Inhaled COVID-19 Treatment Fails in Phase III

  Synairgen watched its stock plummet 85% after reporting disappointing Phase III results for its inhaled COVID-19 treatment on Feb. 21.

  February 22, 2022

   · 

  2 min read

   · 

  Kate Goodwin
• 

  Pharm Country

  Laser Effectively Controls Antigens for 10 Neurodegenerative Diseases in the Lab

  Halberd has demonstrated it can control each of the top 10 antigens associated with various neurodegenerative diseases, including Alzheimer’s, Parkinson’s, epilepsy, TBI and PTSD.

  February 22, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  Mallinckrodt Kidney Drug Derailed Again by FDA CRL

  A new packaging and labeling manufacturing facility has derailed the potential approval of Malinckrodt’s investigational hepatorenal syndrome (HRS) treatment, terlipressin.

  February 22, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  BioNTech and Medigene Link Up for Solid Tumor T-Cell Treatments

  BioNTech and Medigene announced a global agreement to develop T-cell immunotherapies against cancer. The three-year collaboration will focus on multiple solid tumor targets.

  February 22, 2022

   · 

  3 min read

   · 

  Hannah Chudleigh
• 

  Drug Development

  4D Gets Green Light to Test First Live Biotherapeutic for Parkinson’s

  With IND approval, the therapeutics have become the first LBPs for Parkinson’s disease cleared by the FDA.

  February 22, 2022

   · 

  3 min read

   · 

  Hayley Shasteen
• 

  Business

  Ophthalmology Biotech Sees Series A Hit $65M

  Proceeds will be used to assemble and develop a diversified pipeline of therapies to address sight-threatening illnesses.

  February 22, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN